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CD4 T cells play a crucial role during virus infections by producing antiviral cytokines and by regulating humoral and cellular immune
responses. Unfortunately however, exaggerated CD4 T cell responses can cause significant immune-mediated disease as was observed during
RSV infections in children previously vaccinated with a formalin-inactivated virus in the 1960s. It has been observed that vaccination with
the G protein of RSV tends to prime mice for a similar Th2-mediated enhanced disease. Whether the G protein may play a role in enhanced
disease in man is unclear. In the present study, we identified an immunodominant epitope in the conserved region of the G protein
encompassing amino acid residues 162–175. This epitope is presented in the context of HLA-DPB1*0401 and DPB1*0402, the most
prevalent HLA class II alleles. Importantly, in some patients, a mixed Th1/Th2 response against this epitope was found in bronchoalveolar
lavage samples during primary RSV infections.
D 2004 Elsevier Inc. All rights reserved.Keywords: Respiratory syncytial virus; CD4 T cell; MHC class II; Peptide; G protein
Introduction Unfortunately however, the precise mechanism(s) of severeRespiratory syncytial virus is a major cause of childhood
lower respiratory tract infections. Seventy percent of all
children are infected in their first year of life, and nearly all
children by age 3 (Glezen and Denny, 1973). Although the
majority of patients suffer a relatively mild upper respiratory
tract infection, 3% of infected children are hospitalized and
require oxygen support (Shay et al., 2001). Risk factors for a
severe RSV infection are prematurity, congenital heart
disease, and bronchopulmonary dysplasia, although genetic
predisposition also seems to play a role (Simoes, 1999).0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.06.008
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T cells play an important role in clearing the virus from
the infected lung. However, T cells may also be involved in
immune pathology that can be associated with respiratory
disease. An involvement of CD4 T cells with a Th2
phenotype has been postulated as a possible cause of
severe pathology. In children with severe RSV infections,
it has been observed that CD4 T cell responses in periph-
eral blood tend to produce higher levels of Th2 cytokines
than in control populations (Bendelja et al., 2000; Roman
et al., 1997). However, these results could not be repro-
duced by others (Bont et al., 1999; Brandenburg et al.,
2000). Moreover, the presence of eosinophil cationic pro-
tein in broncheolar alveolar lavage fluid and nasal secre-
tions of children with severe RSV infections also suggests
the involvement of local Th2 responses, that is, in the
Table 1
Amino acid sequences of G peptides
G162–175 DFHFEVFNFVPCSI
G165–179 FEVFNFVPCSICSNN
G168–183 FNFVPCSICSNNPTCW
G171–187 VPCSICSNNPTCWAICKa
G174–189 SICSNNPTCWAICKRI
G177–194 SNNPTCWAICKRIPNKKP
G179–194 NPTCWAICKRIPNKKPa
G183–197 WAICKRIPNKKPGKK
G185–199 ICKRIPNKKPGKKTT
Variant sequences
G163A DAHFEVFNFVPCSIa
G165A DFHAEVFNFVPSCIa
G168A DFHFEVANFVPCSIa
G170A DFHFEVFNAVPCSIa
G162–175a DFHFEVFNFVPCSIa
a Peptide amides.
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kines such as IL-5 and IL-13, Th2 cells could be respon-
sible for the recruitment of eosinophils into the lung.
However, no direct evidence exists that Th2 cells and
Th2 cytokines are indeed present in the lungs of patients
with severe RSV infections.
To evaluate the role of CD4 T cells in the immunopath-
ological processes during severe RSV infection, it is essen-
tial to characterize the antigenic specificities of CD4 T cell
responses, and to determine the nature and magnitude of
such responses in the infected lung. For the fusion (F)
protein of RSV, we have recently identified a panel of
immunodominant epitopes that are recognized by memory
CD4 T cells obtained from healthy adult blood donors (van
Bleek et al., 2003). These peptides were localized across the
entire length of the F protein. For the second major surface
protein of RSV, the glycoprotein (G), we focussed our
epitope mapping studies on the conserved antigenic loop
of this highly polymorphic protein. Within this region,
several antigenic peptides have been described that induce
CD4 T cell responses in mice with different genetic back-
grounds (Hancock et al., 2003; Tebbey et al., 1998; Varga et
al., 2000). Moreover, it has been found that these antigenic
peptides derived from the G protein all have the tendency to
induce, to some extent, Th2-type T cell responses. Similarly,
in one human study with short-term T cell lines established
after stimulation of PBMC with purified RSV F and G
proteins, the G specific lines produced Th2-type cytokines,
whereas F stimulated PBMC cultures produced Th1-type
cytokines (Jackson and Scott, 1996).
Here, we present the characterization of a dominant
epitope that is presented in the context of HLA-
DPB1*0401 and *0402. These HLA class II molecules
are present worldwide in an allelic frequency of 20–60%
and cover about 75% of the Caucasian population (Al
Daccak et al., 1991; Castelli et al., 2002). Although the
DP4 binding motive F1–F6 is present twice within the
peptide sequence (Castelli et al., 2002; Falk et al., 1994),
our data suggest the predominant use of only one frame.
Interestingly, two size variants of the peptide induce differ-
ent cytokine profiles. These observations indicate that the
exact length of the naturally produced peptide and the
cognate T cell repertoire, may, in part, determine the
outcome of the CD4 T cell response after natural infection
in terms of cytokine profiles.Results
Identification of RSV-specific T cell epitopes
To identify RSV G derived CD4 T cell epitopes, a set of
overlapping peptides covering the conserved loop area
(amino acid residues 162–199) of the RSV G protein was
synthesized (Table 1). PBMC of healthy adult blood donors
that differed in HLA class II haplotypes were tested in aninterferon-g ELISPOT assay for their response against this
set of peptides. Eight out of ten donors from this panel
recognized a peptide spanning amino acid residues 162–175
(G162–175, Table 2). An overlapping peptide, G165–179,
was recognized by the same donors. A second antigenic
region was found in the stretch of amino acid residues 177–
197 where two sequential peptides, G177–194 and G183–
197, shared amino acid residues 183–194. The first epitope
G162–175 was recognized at levels of 17–200 spots per 106
PBMC. The epitope in the second region was recognized at
levels between 16 and 56 spots per 106 PBMC. These
frequencies are in the same order of magnitude as the CD4
Tcell responses that we have found against epitopes from the
fusion protein of RSV (van Bleek et al., 2003).
RSV-G epitopes are presented by HLA-DP and HLA-DR
To confirm that the T cell responses were in fact MHC
class II restricted and to determine the restriction elements,
we performed T cell stimulation assays in the presence of
blocking antibodies with specificity for HLA-DR (B8.22.1),
HLA-DQ (SPVL2), and HLA-DP (B7/21). As shown in Fig.
1, our data revealed that the epitope(s) in peptides G162–
175 and G165–179 was presented by HLA-DP and that the
epitope(s) in peptides G177–194/G183–197 was presented
by HLA-DR. Since our donor panel had not initially been
typed for HLA-DP, all donors were subjected to DNA
typing. The donors responding to peptides G162–175 and
G165–179 all shared HLA-DPB1*0401 or B1*0402,
whereas the non-responders did not express the DP4 alleles
(Table 2). Three of the responding donors were homozygous
for HLA-DPB1*0401, providing conclusive evidence that
this allele binds and functionally presents the peptide. The
second antigenic region contains peptides that could be
presented by several HLA-DR molecules that were not
further identified at this point. Given the distribution of
positive ELISPOT signals, it seems likely that this area
contains either multiple or promiscuous epitopes (Table 2).
Table2
IFN-g ELISPOT assay performed with PBMC of healthy adult blood donors
DONOR VB-7 CH-1 VB-2 VB-5 VP-1b MP-4 VB-4 VB-6 VB-11 CE-8b
HLA-DRB1 *1101 *15 *0701 *0401 *1302 *1301 *1101 *0401 *15 *03
*15 *16 *1101 *0403 *15 *1301 B4*01 *16
HLA-DPB1 *0401 *0402 *0401 *0401 *0501 *0401 *0401 *0402 *0401 *0901
*02012 *0402 *03011 *02012 *03011 *1401 *01011
G162–175 129a 27 47 200 2 26 52 17 23 1
G165–179 96 14 14 130 4 nd nd 2 20 0
G168–183 5 1 17 4 6 nd nd 6 5 nd
G174–189 10 5 1 2 2 nd nd 2 2 nd
G177–194 56 19 19 20 4 16 20 2 6 2
G183–197 53 1 9 12 2 nd nd 2 4 nd
G185–199 20 4 3 4 2 nd nd 7 2 nd
nd: not done.
a Number of spots per 106 PBMC minus background values of unstimulated samples.
b These donors respond to F derived peptides (Fig. 1 and van Bleek et al., 2003).
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were stimulated for 5 h with peptide G162–175, the T cell
response as measured by intracellular staining for IFN-g
was low (Fig. 2B). However, when PBMC were cultured
with RSV for 10 days, T cells were expanded that produced
IFN-g upon re-stimulation on day 10 with RSV-infected
antigen-presenting cells or peptide G162–175 (Figs. 2D, E).
This result proves that peptide G162–175 or a closely
related peptide is indeed naturally processed and presented
on RSV-infected APC.
Cytokine production induced by G162–175 and G165–179
Because we used the interferon-g ELISPOT assay to
measure peptide-specific responses, it cannot be excluded
that T cells producing other cytokines (e.g., Th2 type) upon T
cell receptor triggering were missed. Therefore, we tested the
T cell response against the G peptides in selected donors by
measuring a set of cytokines in culture supernatants, using a
multiplex cytokine assay (luminex, De Jager et al., 2003).
Although these experiments did not result in the identifica-
tion of additional dominant epitopes (data not shown), we
found that stimulation with the G162–175 and G165–179
peptides elicited strikingly different cytokine profiles. For
donor VB-7 (Table 2), we observed that stimulation with
G165–179 yielded IL-5 and IL-13 and only minor quantities
of IFN-g (Fig. 3B). In contrast, G162–175 induced produc-
tion of predominantly IFN-g. A different pattern was found
in a second donor (Fig. 3A, donor VB-5): here, stimulation
with G165–179 led to reduced levels of IFN-g compared to
G162–175, and no upregulation of Th2-type cytokines. In
both cases, however, the Th1/Th2 cytokine ratio differed
between G162–175 and G165–179 (Fig. 3). These cytokine
patterns were highly reproducible over a broad peptide dose
range, suggesting that rather than the antigen dose the
structural features of the HLA/peptide/T cell receptor com-
plex or the phenotypes of the different memory pools
determined the pattern of the response.Peptide G162–175: one or two binding registers?
For HLA-DP, a binding motif has been described that
consists of two phenylalanine amino acid residues spaced
six positions apart (Castelli et al., 2002; Falk et al., 1994).
This Phe-1/Phe-6 (F1–F6) motif is present twice within the
antigenic peptide G162–175 and once in G165–179 (Fig.
4A). A favored secondary anchor (valine at position 9) is
present only in the amino-proximal motif. Because peptide
G165–179 is able to stimulate T cell responses in most
donors that are HLA-DPB1*0401 positive, it is evident that
the carboxy proximal motif F165/F170 is used for binding
to the groove of this HLA molecule. However, the different
cytokine patterns found in the responses of donors VB5 and
VB7 against the overlapping DP4-restricted peptides might
be an indication that the G162–175 peptide can also bind to
HLA-DP4 in an alternative fashion. In other words, the
G162–175 peptide could comprise two overlapping HLA-
DP restricted epitopes. It seems likely that different sets of T
cells would respond to the peptides, depending on which
register was used for HLA binding. However, it is also
conceivable that G162–175 harbors only a single epitope,
but that the extra N-terminal amino acid residues present in
peptide 162–175 or the additional C-terminal residues in
G165–179 affect the binding with either the HLA molecule
or the T cell receptor.
To distinguish between these possibilities, we synthe-
sized variant peptides with single alanine substitutions at the
positions of the four potential phenylalanine anchor residues
(positions 163, 165, 168, and 170). We used these variant
peptides to stimulate CD4 T cells and measured cytokine
production by luminex. When fresh PBMC from donor VB-
7 were stimulated for 72 h with the peptides containing
substitutions at positions 165 or 170, no cytokine produc-
tion could be measured (Fig. 4B). The peptide variants with
Ala replacements in the first (amino-proximal) binding
register (positions 163 and 168) did induce IFN-g produc-
tion, albeit at lower amounts than the wild-type peptide.
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not shown). Slightly different results were obtained for
donor VB-5: whereas Ala-substitution at position 165 ab-
rogated IFN-g production, the effect was less obvious for
the Ala substitution at position 170, contrasting with the
data for donor VB-7 (Fig. 4C). Mutating F163 and F168 ledFig. 2. Natural processing and presentation of a G162–175 related
sequence in RSV-infected cells. Intracellular staining for IFN-g was
performed on (A) unstimulated PBMC, (B) PBMC stimulated for 5 h with
G162–175, and (C–E) in PBMC cultures grown for 10 days in the
presence of RSVand recombinant IL-2, after a short 5 h re-stimulation with
(D) virus-infected APC or (E) G162–175. (C) Cell cultures that were not
re-stimulated on day 10. The numbers in the upper right quadrants are the
percentage of IFN-g producing CD4 T cells in a live cell and lymphocyte/
lymphoblast gate.to reduced levels of IFN-g production, similar to donor VB-
7. From this experiment, it was concluded that peptides
mutated in the amino-terminal binding register (positions
163 and 168) still bound to HLA-DP. The F residue at
position 165 was clearly essential for binding in both
donors, implicating this amino acid as a crucial anchor
residue, consistent with the fact that this anchor residue is
present in the only motif that is represented in peptide
G165–179. However, the residual response in donor VB-
5 against the 170A mutant peptide showed that measure-
ment of T cell responses against the Ala substituted peptides
was not a sensitive enough procedure to conclusively
determine the involvement of the position of a mutated
amino acid residue in a putative binding motif. Therefore,
the diminished response against the peptides that were
mutated in the NH2 proximal motif cannot be interpreted
as an effect on MHC interaction. Thus, at this point, we
were still unable to exclude the possibility of the second
binding register in peptide G165–179.Fig. 1. HLA molecules involved in the presentation of G epitopes.
Inhibition of IFN-g production by MHC class II specific antibodies B8.11.2
(anti-HLA-DR), SPVL3 (anti HLA-DQ), and B7/21 (anti HLA-DP). (A)
IFN-g ELISPOT assay with PBMC of donor VB7 (HLA-DRB1*1101,
*1501, DPB1*0401) against peptides G162–175 and G183–197. PBMC
of donor VP1 (HLA-DRB1*15, *1302, DQB1*06, DPB1*03011, *0501)
were tested in the same assay against a control peptide F295–312 that was
identified by us before and is presented by HLA-DQ. (B) IFN-g ELISPOT
assay performed with different donors (HLA class II shown in the figure)
against peptide G162–175 at 500 nM and peptide G177–194 at 5 AM. (C)
Cytokine production by PBMC of donor VB-7 stimulated with peptides
G177–194 and G165–179. Grey bars, no blocking antibody added; black
bars, B8.11.2; hatched bars, SPVL3; and white bars, B7/21.
Fig. 3. Cytokine production of PBMC of donor VB-7 (HLA-
DRB1*1501*1101, DPB1*0401) and VB-5 (HLA-DRB1*0401, *0403,
DPB1*0401) upon stimulation with G162–175 and G165–179. The
peptide concentrations tested were 20, 10, 5, 2.5, 1, and 0 AM. White bars,
IFN-g; grey bars, IL-13; and black bars, IL-5.
Fig. 4. (A) Cartoon of the two possible binding registers within peptide
G162–175. Only the second C-proximal binding register is present in
peptide G165–179. (B and C) IFN-g production upon stimulation by
G162–175 (grey bars), mutant peptides with Ala replacements in the
N-proximal binding motif (white bars) and Ala substitutions in the second,
C-proximal binding register (hatched bars), and G165–179 (grey). Black
bars, no peptide added. Peptides were tested in a concentration of 5 AM.
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T cell lines after stimulation of PBMC with peptide G165–
179. We found that these G165–179 stimulated T cells
produced cytokines IFN-g, IL-13, and IL-5 upon re-stimu-
lation with peptide G162–175, showing that within peptide
G162–175 the second, C proximal binding register is
indeed used for HLA binding (Figs. 5A–D). The reverse
experiment, using peptide G162–175 for primary stimula-
tions and G165–179 for re-stimulation, revealed that the
secondary IFN-g response against G165–179 strongly
resembles the recall response with peptide G162–179
(Fig. 5E). No IL-13, IL-5, or IL-10 response was detected
in this case. This result suggested that the response against
G162–175 is dominated by T cells that recognize this
peptide in the second, that is, C-terminal binding register
(see further discussion).
Patients with acute severe primary RSV infections respond
to peptide G162–175
To evaluate the contribution of CD4 T cells specific for
the HLA-DP restricted G epitopes in severe primary RSVinfections, we tested these peptides in peripheral blood
mononuclear cells and in bronchoalveolar lavage (BAL)
samples of patients. The patients were infants, younger than
3 months of age, requiring mechanical ventilation due to
RSV positive bronchiolitis. The HLA-DP haplotype was not
known for these patients. Unfortunately, short-term stimu-
lation of PBL or BAL samples directly ex vivo did not
induce cytokine levels above the detection limit of the
luminex assay. However, after 10 days of culturing, the
cells in the presence of the G peptides, epitope-specific
responses were clearly present in cultures of BAL cells from
two out of five patients tested (Fig. 6) and not in cultures
from PBMC (data not shown). In one patient, we detected
Fig. 5. Cytokine production by in vitro cultured PBMC of donor VB-7.
PBMC stimulated once with G165–179 (A–D) and with G162–175 (E)
were from day 5 onwards expanded in IL-2. On day 11 after primary
stimulation, the cells received a second stimulus with G162–175 (G162),
the amide form of G162–175 (G162*), or with G165–179 (G165), or were
left unstimulated. Cytokines were measured by luminex 72 h after re-
stimulation. The cultures that received as primary stimulation peptide
G162–175 did not produce significant amounts of IL-13, IL-5, IL-10.
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vitro re-stimulation on day 10 with peptide G162–175. IL-4
and IL-5 were not detected. The cultures of the second
patient showed IL-5, IFN-g, Il-10, and IL-13 production but
no TNF-a production upon re-stimulation with peptide
G162–175. The culture of the second patient also
responded to re-stimulation with peptide G165–179. These
results demonstrate that responses against the G epitope are
elicited during primary infections. Future studies will ad-
dress the contribution and type of G-specific CD4 T cell
responses in larger patient populations.Fig. 6. Cytokine production of non-bronchoscopic BAL samples of two
patients with RSV. Cells were stimulated in vitro for 10 days with peptide
G162–175 or G165–179. After a re-stimulation for 24 h with the same
peptides used during primary stimulation, cytokines were assayed in the
culture supernatants by luminex. White bars, no peptide; black bars, peptide
G162–175; grey bars, G165–179.Discussion
In the present study, we have characterized antigenic
epitopes in the conserved region of the RSV G protein,
which are recognized by human CD4 T cells. Two regions
were found, each containing two overlapping peptides that
were able to induce a response in T cells of healthy blooddonors without prior in vitro culture of the cells. The fact
that one of the epitopes is presented by HLA-DP4 is
important, since it allows a further analysis of G-specific
CD4 T cell responses in a large group of patients because
HLA-DP4 is widely expressed within the world population.
Moreover, we were able to measure responses against
G162–175 in almost every HLA-DP4 positive adult donor,
which indicates that the response to this peptide is a general
event and that the epitope should be qualified as immuno-
dominant. Two donors that responded to peptide G162–175
(CH-1 and MP-4, Table 2) expressed HLA-DPB1*02012 in
addition to a DP4 allelic product. DPB1*02012 differs in
only one amino acid residue from DPB1*0402. At this
point, we cannot exclude the possibility that also HLA-
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G epitope.
One of the most striking observations of our study is that
two different donors homozygous for HLA-DPB1*0401
responded with different cytokine patterns against peptide
G165–179. This could suggest that the responding T cell
repertoire present in a certain individual could, in part,
determine the type of immune response elicited against
RSV. Because we measured direct ex vivo T cell responses,
it seems likely that we observed memory T cell responses
caused by previous exposure to RSV. Therefore, the differ-
ences in the cytokine profiles for the two donors could be
caused by differences in the composition of the memory
pools, that is, reactivation of Th1-type cells in one donor
and Th2-type cells in the other donor. However, it is also
possible that not pre-existing (memory) T cell polarization
but the structural features of the interaction of the MHC/
G165–179 complex with the memory T cell receptors
determined the outcome of the Th2-type response. This
second interpretation that in vitro (re-) stimulation with
length variants of epitopes results in qualitative different T
cell responses would imply that the memory populations are
still subject to final polarization. Careful examination of T
cell receptor usage in the responding T cell populations
would possibly clarify this issue. Interestingly, during the
review process of our manuscript, a report was published by
the De Waal et al. (2004) describing T cell clones that
recognized the same region of the RSV G protein that we
found. Using overlapping peptides, de Waal et al. found that
two T cell clones recognized slightly different minimal
epitopes encompassing amino acid residues 164–170 and
166–171, respectively. The first minimal epitope is only
completely contained in peptide G162–175, and the second
in both G162–175 and G165–179. These two clones show
that T cells that recognize this area of the G protein may do
so requiring different contact residues in the peptide. It is
unclear however whether this different fine specificity could
be responsible for the different cytokine profiles that we
observed when PBMC of different donors were stimulated
with peptide G162–175 or G165–179.
The choice of differentiation into either Th1 or Th2 cells
is a crucial step that determines the direction of the subse-
quent adaptive immune response. Many factors can influ-
ence this choice, such as (i) the local cytokine environment
during T cell priming, (ii) the duration of the contact
between the T cell receptor and its ligand, and (iii) the
quality of co-stimulatory signals (Constant and Bottomly,
1997). The duration of contact is influenced by the density
of peptide-MHC ligand on the antigen-presenting cell, the
stability of the interaction between peptide and MHC, and
the duration of the half-life of T cell receptor–MHC com-
plexes. Upon interaction of T cells with APC, reciprocal
activation of both cell types occurs. Increased binding
affinity between the T cell receptor and the peptide MHC
complex increases the expression of CD40 ligand on the T
cell, which induces improved conditioning of the antigen-presenting cell as can be measured by increased production
of IL-12 and altered expression of co-stimulatory molecules
B7-1 and B7-2 (Ahlers et al., 2001). MHC class II bound
peptides are presented on the cell surface as large nested sets
that vary in length at the NH2 and COOH termini. Thus,
outside of the HLA class II binding core, variable numbers
of flanking amino acid residues can be present. These
flanking regions can impact dramatically on MHC-peptide
stability (Godkin et al., 1998). Moreover, a substantial
number of T cells are functionally dependent on recognition
of peptide flanking regions (Arnold et al., 2002; Carson et
al., 1997; Chang and Braciale, 2002). Thus, the exact length
of a peptide that is naturally presented is a crucial factor that
can influence the nature of the immune response. Therefore,
elution of the naturally processed epitope(s) from HLA-DP
molecules, after exposure of antigen-presenting cells to
RSVor soluble G protein, is required to prove the relevance
of the observation that different cytokine responses are
induced by synthetic epitopes.
Compared to HLA-DR, HLA-DP is less frequently
reported as antigen-presenting molecule. However, the list
of antigenic peptides that are functionally presented is
growing steadily and covers different types of antigenic
sources varying from viruses (Celis and Karr, 1989; Celis et
al., 1990; Eckels et al., 1983), fungi (Chang et al., 2000) and
tumors, (Schultz et al., 2000; Zeng et al., 2001) to myco-
bacteria (Gaston et al., 1990) and house dust mite (Higgins
et al., 1994) antigens. Also, there have been some reports of
disease associations with HLA-DP molecules (Begovich et
al., 1989; Galeazzi et al., 1992). HLA-DR, DQ, and DP are
expressed to different levels, with DR being most abun-
dantly expressed on most APC (Robbins et al., 1988;
Roucard et al., 1996). Both HLA-DR and HLA-DP are also
constitutively expressed on airway epithelial cells (Cunning-
ham et al., 1994). The expression of the different HLA class
II molecules is differently regulated (Coiras et al., 2002; De
Lerma et al., 1994; Douhan et al., 1997; Muczynski et al.,
1998; Peretti et al., 2001; Redondo et al., 1998; Zhou et al.,
1997). However, to our knowledge there are no clear
indications that antigen presentation by different HLA
isotypes induces a distinct type of immune response.
In murine models of RSV infection, it has clearly been
shown that, in comparison to the other viral proteins, the G
protein has a stronger tendency to sensitize mice for Th2-
type CD4 responses, which are associated with enhanced
disease after viral challenge (Alwan and Openshaw, 1993;
Johnson et al., 1998; Varga et al., 2001). However, the
potential role of pathogenic G-specific CD4 T cell responses
should not be overinterpreted. First, in mice, it is clear that
both the route of administration of the protein vaccine and
the form in which it is applied affects the outcome of the
ensuing immune response (Bembridge et al., 1998; Plotn-
icky-Gilquin et al., 1999). Second, in the setting of primary
or secondary RSV infection, the (virus-induced) G-specific
CD4 T cell response did not appear to cause significant
immune pathology. Finally, enhanced disease in mice after
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formalin-inactivated (FI) virus that lacks the G and SH
proteins (Polack et al., 2002). Therefore, the G protein does
not seem to play a unique role as the primary cause of
enhanced disease in mice. We found Th2 cytokines in only
one of the two patients that responded to the G epitopes.
Further studies with more patients are currently being
conducted in our laboratory to determine the relative con-
tribution of Th1 and Th2 responses against G- and F-derived
epitopes during primary RSV infections.
For future vaccine development, the role of T cells during
severe primary RSV infections in infants needs to be
addressed, as well as the role of specific viral components
therein. The results of previously published studies address-
ing the role of Th2-type cytokines during RSV disease are
conflicting. There are reports that suggest a Th2 skewed T
cell responsiveness during RSV infections (Bendelja et al.,
2000; Joshi et al., 2003; Legg et al., 2003) while others
report predominant Th1-type responses in RSV patients
(Bont et al., 1999; Brandenburg et al., 2000). Part of the
reason for these discrepancies may be the source of tissue
sampled, that is, peripheral blood vs. nasal secretions or
bronchoalveolar lavage, which are used for the assays.
Moreover, different methods of analysis—T cell stimulation
assays or direct cytokine measurements—may have contrib-
uted to the different results. From mouse studies, it was
learned that local T cell responses in the lung may differ
from the type of T cell response observed in the spleen
(Varga et al., 2001). Likewise, it can be expected that the
analysis of antiviral T cell responses in peripheral blood of
patients may not properly reflect the events in the lung.
Knowing the antigenic epitopes presented by HLA may
contribute to clarifying the role played by T cells in the lung
and this knowledge may guide the development of vaccines.Material and methods
Peripheral blood mononuclear cell preparation
Buffy coats were obtained from healthy adult blood
donors. Since (i) all children have been exposed to RSV
by the age of 3 and (ii) adults are re-exposed to RSV every
2–3 years, we assumed that all adult donors have been
primed with RSV and harbor memory responses. PBMC
were isolated by density centrifugation with lymphoprep
(Nycomed Pharma). PBMC where either used fresh or
thawed from cryopreserved samples [liquid nitrogen, in
RPMI, 30% fetal bovine serum (HyClone) supplemented
with 10% DMSO].
Synthetic peptides
Peptides were synthesized by standard solid-phase Fmoc
chemistry. The sequences of the peptides used are given in
Table 1. Peptides were either made with a free carboxyterminus or with an amino-terminal amide, as indicated in
Table 1.
Patient studies
The patients included were admitted to the pediatric
intensive care unit of the Wilhelmina Children’s Hospital
in the winter season of 2002–2003. The infants were under
3 months of age and required mechanical ventilation be-
cause of respiratory failure due to RSV lower respiratory
tract infection. PBMC of the children were prepared using
the same procedure that was applied for adult blood sam-
ples. Nonbronchoscopic bronchoalveolar lavage (NB-BAL)
was performed twice as described before (Schindler and
Cox, 1994) using 1 ml/kg saline at room temperature.
Collected samples were directly placed on ice. Specimens
were filtered through 70-AM cell strainers (Falcon, BD) to
remove mucus. No DTT was used to dissolve the mucus to
avoid possible denaturation of cell surface proteins involved
in T cell receptor–target cell interaction. Cells were cry-
opreserved in 90% fetal bovine serum with 10% DMSO in
liquid nitrogen. Before the assays, PBMCs and BAL were
quickly thawed and washed twice. Cells were plated in
duplicate at 5  106 cells/well in 96-well round bottom
plates in AIM-V medium (Gibco) supplemented with 2%
human pooled serum (HPS) and 40 units/ml recombinant
human IL-2. One micromolar of the appropriate peptide was
added to the cells in a total volume of 225 Al. Cells were
allowed to proliferate for 10 days with medium replacement
when needed. On day 10, cells were split into two new wells
and re-stimulated with the same peptide in a total volume of
100-Al medium. After 48 h, supernatants were sampled and
cytokines were measured using the Luminex multiplex
cytokine assay. Healthy donors and parents of patients gave
their informed consent. The study was approved by the
Medical Ethical Committee of the University Medical
Center of Utrecht.
HLA-DPB1 sequencing-based typing (SBT)
SBT was performed according to the previously pub-
lished approach (Rozemuller et al., 1993; Versluis et al.,
1993). Full exon 2, containing all allele representative
polymorphism was sequenced and ambiguous allele combi-
nations resolved by group-specific amplification and subse-
quent sequencing (Versluis et al., 1995).
Intracellular staining of peptide-specific T cells for flow
cytometry
PBMC were plated in a 96-well round bottom plate
(Costar) (0.5  106 cells/well) in AIM-V medium supple-
mented with P/S, 2% HPS, 40 units/ml IL-2, and costi-
mulatory antibodies (anti-CD28 and anti-CD49d). Cells
were either stimulated with 1 AM of peptide or not
stimulated (negative control). After 1 h of incubation at
P.M.A. de Graaff et al. / Virology 326 (2004) 220–23022837 jC, 10 Ag/ml of Brefeldin A (BD PharMingen) was
added to accumulate cytokines in the cell. After 5 h, 2 mM
of EDTA was added to arrest activation and to remove
adherent cells from the well. After incubating 20 min at
room temperature, cells were washed twice in FACS buffer
(PBS containing 0.02% azide, 2% FCS, and 2 mM EDTA).
Then phycoerythrin (PE)-labeled anti-CD3 mAb (BD-Phar-
Mingen) and Cy5-labeled anti-CD8 mAb (BD-PharMin-
gen) for surface staining were added. After 30 min of
incubation on ice, cells were washed twice in ice-cold
FACS buffer. Cells were permeabilized and fixated using
FACS permeabilizing/fixation solution (perm/Fix) (BD-
PharMingen). Cells were stained intracellularly after an
additional wash in Perm-wash (BD-PharMingen) with
fluorescein isothiocyanate (FITC)-labeled IFN-g mAb
(BD-PharMingen clone 340449) for 30 min on ice. Cells
were washed three times in perm-wash and fixated in 1%
paraformaldehyde/PBS for 20 min. Cells were resuspended
in FACS buffer and kept at 4 jC until analysis. Cell
staining was analyzed on a FACS-Calibur using CellQuest
software (BD Bioscience, Mountain View, CA). To eval-
uate whether the G epitopes were presented during infec-
tion, PBMC were infected with RSV at a MOI of 5 and
cultured in 24-well plates (1  106/well) in AIM-V
medium with 2% (HPS), (P/S), and 40 units/ml of recom-
binant human IL-2. After 10 days of proliferation, cells
were either stimulated with the peptide or not re-stimulated
(negative control). On day 8, PBMC of the same donor
were depleted for CD3+ T cells using negative selection
MACS separation columns (Miltenyi Biotec, Germany).
The remaining cells were infected with RSV at a MOI of 5
2 days before use, thus allowing the APC to present RSV
epitopes. On day 10, these APC were added to the PBMC
that had been stimulated with RSV on day 0. Stimulation
with peptide or virus-infected APC was allowed for 5 h in
the presence of Brefeldin-A. Intra- and extracellular stain-
ing was performed as described.
ELISPOT assay
ELISPOT assays for INF-g production were performed
as described before, using antibodies 1-D1K and 7-B6-1-
biotin (Mabtech) for coating and detection, respectively.
Monoclonal antibodies used for the blocking of antigen
presentation by HLA-DR (B8.11.2), HLA-DQ (SPVL3),
and anti HLA-DP (B7/21) (Watson et al., 1983) were used
as diluted culture supernatants. After coating of the filtration
plates with 1-D1K, the plates were washed thoroughly and
blocked with RPMI 1640 containing 10% fetal bovine
serum. PBMC (2.5  105) were then added to the plates
together with the indicated amount of peptides. When
antibody blocking was performed, the cells and blocking
antibodies were pre-incubated for 30 min at 37 jC, after
which the peptides were added to the cultures. Cells were
cultured with antigen for 24 h at 37 jC in a humidified
incubator, before the addition of detection antibodies. Inmost experiments, peptides were titrated in the presence of a
constant concentration of blocking antibody. The result of
antibody blocking presented in the figures is the lowest
peptide concentration that still induces (close to) maximal
levels of interferon-g production. Data are represented as the
number of spots per 106 PBMC, minus the background of
unstimulated samples.
Multiplex cytokine assay
Multiplex cytokine analysis was applied using a proce-
dure that has been described in detail (De Jager et al., 2003).
This procedure is a particle-based ELISA-type assay based
on the bioplex system and employing the luminex multi-
analite profiling technology. In our laboratory, this tech-
nique is used to identify 17 different cytokines within a
single sample. The antibody pairs used for the experiments
in the present study are all the same as described earlier (De
Jager et al., 2003). For our application, we reduced the
number of cytokines to seven [interleukin (IL)-2, IL-4, IL-5,
IL10, IL-13, TNF-a, IFN-g]. Antigen stimulation was
performed with PBMC, 5  105 or 106 per well, in 96-well
round bottom plates (Costar) in triplicate in RPMI 1640
supplemented with penicillin/streptomycin and 10% fetal
bovine serum. Peptides were added to the wells at concen-
trations given in the figure legends. Culture supernatants
were routinely sampled at 24, 48, and 72 h. In the figures,
cytokine concentrations present in culture supernatants
harvested after 72 h are depicted. Cytokines that were not
produced above background levels are omitted from the
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